Recipharm has begun negotiations with the pharmaceutical company LIDDS about collaborating on making Liproca Depot® ahead of continued clinical development and a potential future market launch.
The companies explained in a joint letter their intention to initiate collaboration in the areas of scale-up, manufacture and quality assurance of LIDDS’ pharmaceutical products. Initially the companies will focus on Liproca®Depot, a targeted treatment for prostate cancer currently in Phase II, but they may also look at other products based on LIDDS’ technology platform. The letter of intent follows a feasibility study performed by Recipharm, which determined that a manufacturing process that ensures a high-quality end product could be developed.
“Collaboration with a manufacturing partner as renowned as Recipharm increases the power of attraction of our prostate-cancer product Liproca®Depot,” says Monica Wallter, LIDDS’ CEO. “A high-quality and cost-effective manufacturing process increases the chances of being able to offer better treatment to patients with prostate cancer in the future.”
“We look forward to contributing with our technical expertise in the field of manufacturing, so in the future cancer patients can be offered treatments associated with fewer side effects,” says Maria Lundberg, generalm manager Recipharm Pharmaceutical Development.